ACE Inhibitors: Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topics. Volume 1

Macaulay Amechi Onuigbo, MD (Editor)
College of Medicine, Mayo Clinic, Rochester, MN, USA

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

Clear

$205.00

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

This book, published in two volumes, Volume 1 and Volume 2, respectively, represents the most comprehensive and up-to-date collection of current literature on angiotensin inhibition and related topics in medicine, nephrology and cardiovascular medicine ever compiled. Top experts in the various fields of nephrology, hypertension, cardiovascular medicine, pharmacotherapeutics and related fields from all five continents have contributed essays, original papers, reviews and editorial opinions to this volume.

This book has turned out to be the most authoritative reference source on ACEIs, with contributions made by leading experts in their various fields of medicine, from the USA, Europe, including the United Kingdom, South America, Australia-New Zealand, Asia including Japan, and Africa. Critically vital clinical topics are covered in this book by top world-renowned experts in different subspecialties, including classic topics such as the efficacy of ACE inhibition as an antihypertensive among the various ethnicities and races, as written from American, African, Caribbean and European perspectives.

This volume should indeed serve as a major literature reference text for physicians in general, internists, researchers, cardiologists and hypertension specialists, and especially the practitioners of the art of nephrology in all the countries around the world. Medical students and various physician training programs should reach for a copy of this volume as a research and teaching tool for many years to come. There is also a place here for research scientists in the pharmaceutical industry to review current and newly emerging indications for angiotensin inhibition and the future of reno-protection. (Imprint: Nova Biomedical )

Special Preview
Zbylut J. Twardowski, M.D., Ph.D., F.A.C.P.

Foreword
Richard J. Glassock, M.D., M.A.C.P.

Preface

Acknowledgments

Cognitive Drift Poem

Section 1. Introduction to ACE Inhibitors and Angiotensin Receptor Blockers in Clinical Medicine

Chapter 1 - The Introduction of Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) into Clinical Medicine and the Mechanisms of Actions of ACEIs and ARBs (pp. 3-12)
Macaulay Amechi Onuigbo, M.D., M.Sc., F.W.A.C.P., F.A.S.N., M.B.A and Ngozi Janet Achebe, M.D. (College of Medicine, Mayo Clinic, Rochester, MN, USA, and others)

Section 2. ACE Inhibitors, Angiotensin Receptor Blockers, Chronic Kidney Disease, Randomized Controlled Trials and the Nephrology Literature

Chapter 2 - RCTs Revisited: A Nephrologist‘s Critique of Randomized Controlled Trials in the Nephrology Literature (pp. 15-34)
Zbylut J. Twardowski, M.D., Ph.D., F.A.C.P. and Madhukar Misra, M.D., F.R.C.P. (Division of Nephrology, Department of Medicine, University of Missouri, Columbia, MO, USA)

Chapter 3 - The Abuse of Renal Surrogates and Combination Renal Endpoints in Nephrology RCTs (pp. 35-40)
Macaulay Amechi Onuigbo, M.D., M.Sc., F.W.A.C.P., F.A.S.N., MBA (College of Medicine, Mayo Clinic, Rochester, MN, USA, and others)

Chapter 4 - The CKD Enigma, Reengineering CKD Care, Narrowing Asymmetric Information and Confronting Ethicomedicinomics in CKD Care: The Introduction of the New 'CKD Express©' IT Software Program (pp. 41-56)
Macaulay Amechi Onuigbo, M.D., M.Sc., F.W.A.C.P., F.A.S.N., M.B.A, ChiChi Onuigbo, Victor Onuigbo, B.S., Mark Onuigbo, B.S.E., Nnonyelum Onuigbo, M.Sc., Manish Joshi, M.B.A. and Obi Egbuniwe, M.I.S., M.B.A., Ph.D. (College of Medicine, Mayo Clinic, Rochester, MN, USA, and others)

Section 3. Adverse Drug Effects of ACE Inhibitors and Angiotensin Receptor Blockers and Related Topics

Chapter 5 - The "Triple Whammy" Challenge Revisited – ACEIs, Diuretics and NSAIDs: A European 21st Century Perspective (pp. 59-62)
Jean-Pascal Fournier, M.D., Ph.D. (Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, Université Paul Sabatier, Toulouse, France, and others)

Chapter 6 - "Quadruple Whammy": A Newly Described Preventable Syndrome of Peri-Operative AKI on CKD in Patients on Concurrent "Triple Whammy" Medications (pp. 63-74)
Macaulay Amechi Onuigbo, M.D., M.Sc., F.W.A.C.P., F.A.S.N., M.B.A., Belmarie P. Roman-Maradiaga, M.D. and Ngozi Janet Achebe, M.D. (College of Medicine, Mayo Clinic, Rochester, MN, USA, and others)

Chapter 7 - Late Onset Renal Failure from Angiotensin Blockade (LORFFAB) – The Results of a Mayo Clinic Health System Angiotensin Inhibition Withdrawal Study: A Clarion Call for More Preventative Nephrology, also Called Renoprevention (pp. 75-90)
Macaulay Amechi Onuigbo, M.D., M.Sc., F.W.A.C.P., F.A.S.N., M.B.A. and Ngozi Janet Achebe, M.D. (College of Medicine, Mayo Clinic, Rochester, MN, USA, and others)

Chapter 8 - Acute Kidney Injury on Chronic Kidney Disease - The Rainbow Syndrome of Too Many Colors: A Mayo Clinic Health System Case Series Report (pp. 91-108)
Macaulay Amechi Onuigbo, M.D., M.Sc., F.W.A.C.P., F.A.S.N., M.B.A. and Ngozi Janet Achebe, M.D. (College of Medicine, Mayo Clinic, Rochester, MN, USA, and others)

Chapter 9 - The Syndrome of Rapid Onset ESRD in the Last 100 Consecutive Incident Northwestern Wisconsin Mayo Clinic Chronic Hemodialysis Patients, 2010-2011: Results of the Analysis of Individual Patient-Level Serum Creatinine Trajectories to ESRD – Can There Be a Link with Angiotensin Inhibition and Renal Senescence in Older CKD Patients? (pp. 109-126)
Macaulay Amechi Onuigbo, M.D., M.Sc., F.W.A.C.P., F.A.S.N., M.B.A., Ngozi Janet Achebe M.D. and Carlos G. Musso M.D., Ph.D. (College of Medicine, Mayo Clinic, Rochester, MN, USA, and others)

Chapter 10 - Geriatric Nephrology Debate: Angiotensin Inhibition Should be Withdrawn in Older Adults with Later Stage CKD: A 2013 Mayo Clinic Health System Nephrologist‘s Perspective and the Unmet Need for Newer Kidney-Friendly Renoprotective Agents for the 21st Century (pp. 127-146)
Macaulay Amechi Onuigbo, M.D., M.Sc., F.W.A.C.P., F.A.S.N., M.B.A. (College of Medicine, Mayo Clinic, Rochester, MN, USA, and others)

Section 4. New Basic Science Studies of ACE Inhibitors

Chapter 11 - Zofenopril: A Sulphydryl ACE Inhibitor Endowed with Antioxidant and Cardioprotective Activity (pp. 149-178)
Stefano Evangelista, M.D. (Department of Preclinical Development, Menarini Ricerche Spa, Firenze, Italy)

Chapter 12 - Molecular Mechanisms and Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors (pp. 179-198)
Daisuke Yamamoto, Ph.D., Shinji Takai, Ph.D. and Merry L. Lindsey, Ph.D. (Biomedical Computation Center and Department of Pharmacology, Osaka Medical College, Takatsuki, Osaka, Japan and others)
Free Download Available

Chapter 13 - Hypertension and Angiotensin-Converting Enzyme Inhibitors in Rat Cardiac Microvessels – A Mini Review of Histochemical Microvascular Studies (pp. 199-210)
Tomiyasu Koyama, Ph.D. (Hokkaido University, Sapporo, Japan)

Chapter 14 - Action Mechanism of Angiotensin I-Converting Enzyme Inhibitory Peptides Derived from Cowpea (Vigna unguiculata) (pp. 211-228)
Maira Segura-Campos, Ph.D., Luis Chel-Guerrero, Ph.D. and David Betancur-Ancona, Ph.D. (Facultad de Ingeniería Química, Universidad Autónoma de Yucatán, Mérida, Yucatán, México)

Chapter 15 - Effect of Angiotensin-Converting Enzyme Inhibitors on Arterial Stiffness and Endothelial Dysfunction: A Comprehensive Review (pp. 229-262)
Yousef Shahin, M.D. (Academic Vascular Surgery Unit, Hull York Medical School and University of Hull, Hull, UK)

About the Editor

Index

Click here, to read the review by - Dr. Dwomoa Adu, Honorary Consultant Physician, Department of Medicine and Therapeutics, University of Ghana Medical School, Accra, Ghana.

You have not viewed any product yet.